Here are three notes:
1. Needham & Company also raised CONMED’s price target to $52.
2. Needham & Company analyst Mike Matson noted that the company’s new management, sales incentive changes, sales force hires and new products will help “drive revenue growth into the mid-single digits or better over the next two years” and he expects this to “drive EBITDA and multiple expansion.”
3. CONMED shares closed at $46.06 on May 1.
More articles on devices:
Anika Therapeutics’ total revenue up 44% to $22.3M — 5 things to know
Zimmer Biomet, NuVasive, Wenzel Spine & more: 21 key notes
Stryker to launch Tritanium Posterior Lumbar Cage: 4 takeaways
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
